Skip to main content
. 2023 Jul 11;16(7):994. doi: 10.3390/ph16070994

Figure 1.

Figure 1

Number of adverse event reports (AERs) involving semaglutide, other glucagon-like peptide-1 (GLP-1) analogues (dulaglutide, liraglutide, exenatide, lixisenatide, tirzepatide, and albiglutide), and the combination phentermine–topiramate. Data source: Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS; 2018–2022). Legend: semaglutide: blue color; other GLP-1 analogues: orange; phentermine–topiramate: grey.